Historic Output Of Disease-Specific Guidances Is Among Gottlieb's Legacies At US FDA

A Pink Sheet analysis illustrates how the outgoing commissioner enhanced FDA's ability to facilitate the further development of innovative drugs. 

At the beginning of his tenure, now-outgoing US FDA Commissioner Scott Gottlieb said the agency will be prioritizing the development of disease-specific guidance documents as a way to facilitate innovative drug development. (Also see "FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development" - Pink Sheet, 12 September, 2017.) He certainly looks to have kept that promise.

A Pink Sheet analysis of FDA guidance documents shows that FDA issued 36 disease-specific guidances during Gottlieb's nearly 22 months...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet